Furthermore, Wnt (porcupine) inhibitors and PI3K inhibitors are currently in clinical trials for other solid malignancies and our data supports recent findings in pancreatic cancer (51), that treating patients with Wnt and PI3K inhibitors provides an attractive therapeutic route to reduce tumor burden. Here, PIK3CA is linked to familial pancreatic carcinoma.